The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …

This paper explores the transformative role of pharmacists in integrating pharmacogenomics
into clinical practice. Pharmacogenomics, the study of genetic influences on drug response …

Major Depressive Disorder (MDD) is a highly prevalent psychiatric disorder worldwide. It
causes individual suffering, loss of productivity, increased health care costs and high suicide …

Objectives With increasing evidence for the clinical utility of pharmacogenomic (PGx) testing
for depression, there is a growing need to consider issues related to the clinical …

Many practitioners who have not had pharmacogenomic education are required to apply
pharmacogenomics to their practices. Although many aspects of pharmacogenomics are …

Objective To assess knowledge, attitudes, and barriers as well as ethical, legal and social
concerns towards pharmacogenetic (PGx) testing among pediatric psychiatrists and …

Pharmacogenetic (PGx) testing has emerged as a tool for predicting a person's ability to
process and react to drugs. Despite the growing evidence‐base, enthusiasm, and …

In this narrative, we evaluate the role of pharmacogenetics in psychiatry from a pragmatic
clinical perspective and address current barriers of clinical implementation of …

Introduction Genetic variation is known to affect enzymatic activities allowing differentiating
various metabolizer types (eg, slow or rapid metabolizers), in particular CYP2C19 and …

Objective To assess perspectives on pharmacogenetic (PGx) testing among members of the
American Association of Geriatric Psychiatry (AAGP). Design Cross-sectional survey …